Cargando…
FDG-PET in presymptomatic C9orf72 mutation carriers
OBJECTIVE: Our aim is to investigate patterns of brain glucose metabolism using fluorodeoxyglucose positron emission tomography (FDG-PET) in presymptomatic carriers of the C9orf72 repeat expansion to better understand the early preclinical stages of frontotemporal dementia (FTD). METHODS: Structural...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8170157/ https://www.ncbi.nlm.nih.gov/pubmed/34049163 http://dx.doi.org/10.1016/j.nicl.2021.102687 |
_version_ | 1783702179539845120 |
---|---|
author | Popuri, Karteek Beg, Mirza Faisal Lee, Hyunwoo Balachandar, Rakesh Wang, Lei Sossi, Vesna Jacova, Claudia Baker, Matt Shahinfard, Elham Rademakers, Rosa Mackenzie, Ian R.A. Hsiung, Ging-Yuek R. |
author_facet | Popuri, Karteek Beg, Mirza Faisal Lee, Hyunwoo Balachandar, Rakesh Wang, Lei Sossi, Vesna Jacova, Claudia Baker, Matt Shahinfard, Elham Rademakers, Rosa Mackenzie, Ian R.A. Hsiung, Ging-Yuek R. |
author_sort | Popuri, Karteek |
collection | PubMed |
description | OBJECTIVE: Our aim is to investigate patterns of brain glucose metabolism using fluorodeoxyglucose positron emission tomography (FDG-PET) in presymptomatic carriers of the C9orf72 repeat expansion to better understand the early preclinical stages of frontotemporal dementia (FTD). METHODS: Structural MRI and FDG-PET were performed on clinically asymptomatic members of families with FTD caused by the C9orf72 repeat expansion (15 presymptomatic mutation carriers, C9orf72+; 20 non-carriers, C9orf72-). Regional glucose metabolism in cerebral and cerebellar gray matter was compared between groups. RESULTS: The mean age of the C9orf72+ and C9orf72- groups were 45.3 ± 10.6 and 56.0 ± 11.0 years respectively, and the mean age of FTD onset in their families was 56 ± 7 years. Compared to non-carrier controls, the C9orf72+ group exhibited regional hypometabolism, primarily involving the cingulate gyrus, frontal and temporal neocortices (left > right) and bilateral thalami. CONCLUSIONS: The C9orf72 repeat expansion is associated with changes in brain glucose metabolism that are demonstrable up to 10 years prior to symptom onset and before changes in gray matter volume become significant. These findings indicate that FDG-PET may be a particularly sensitive and useful method for investigating and monitoring the earliest stages of FTD in individuals with this underlying genetic basis. |
format | Online Article Text |
id | pubmed-8170157 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-81701572021-06-09 FDG-PET in presymptomatic C9orf72 mutation carriers Popuri, Karteek Beg, Mirza Faisal Lee, Hyunwoo Balachandar, Rakesh Wang, Lei Sossi, Vesna Jacova, Claudia Baker, Matt Shahinfard, Elham Rademakers, Rosa Mackenzie, Ian R.A. Hsiung, Ging-Yuek R. Neuroimage Clin Regular Article OBJECTIVE: Our aim is to investigate patterns of brain glucose metabolism using fluorodeoxyglucose positron emission tomography (FDG-PET) in presymptomatic carriers of the C9orf72 repeat expansion to better understand the early preclinical stages of frontotemporal dementia (FTD). METHODS: Structural MRI and FDG-PET were performed on clinically asymptomatic members of families with FTD caused by the C9orf72 repeat expansion (15 presymptomatic mutation carriers, C9orf72+; 20 non-carriers, C9orf72-). Regional glucose metabolism in cerebral and cerebellar gray matter was compared between groups. RESULTS: The mean age of the C9orf72+ and C9orf72- groups were 45.3 ± 10.6 and 56.0 ± 11.0 years respectively, and the mean age of FTD onset in their families was 56 ± 7 years. Compared to non-carrier controls, the C9orf72+ group exhibited regional hypometabolism, primarily involving the cingulate gyrus, frontal and temporal neocortices (left > right) and bilateral thalami. CONCLUSIONS: The C9orf72 repeat expansion is associated with changes in brain glucose metabolism that are demonstrable up to 10 years prior to symptom onset and before changes in gray matter volume become significant. These findings indicate that FDG-PET may be a particularly sensitive and useful method for investigating and monitoring the earliest stages of FTD in individuals with this underlying genetic basis. Elsevier 2021-04-25 /pmc/articles/PMC8170157/ /pubmed/34049163 http://dx.doi.org/10.1016/j.nicl.2021.102687 Text en © 2021 Published by Elsevier Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Regular Article Popuri, Karteek Beg, Mirza Faisal Lee, Hyunwoo Balachandar, Rakesh Wang, Lei Sossi, Vesna Jacova, Claudia Baker, Matt Shahinfard, Elham Rademakers, Rosa Mackenzie, Ian R.A. Hsiung, Ging-Yuek R. FDG-PET in presymptomatic C9orf72 mutation carriers |
title | FDG-PET in presymptomatic C9orf72 mutation carriers |
title_full | FDG-PET in presymptomatic C9orf72 mutation carriers |
title_fullStr | FDG-PET in presymptomatic C9orf72 mutation carriers |
title_full_unstemmed | FDG-PET in presymptomatic C9orf72 mutation carriers |
title_short | FDG-PET in presymptomatic C9orf72 mutation carriers |
title_sort | fdg-pet in presymptomatic c9orf72 mutation carriers |
topic | Regular Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8170157/ https://www.ncbi.nlm.nih.gov/pubmed/34049163 http://dx.doi.org/10.1016/j.nicl.2021.102687 |
work_keys_str_mv | AT popurikarteek fdgpetinpresymptomaticc9orf72mutationcarriers AT begmirzafaisal fdgpetinpresymptomaticc9orf72mutationcarriers AT leehyunwoo fdgpetinpresymptomaticc9orf72mutationcarriers AT balachandarrakesh fdgpetinpresymptomaticc9orf72mutationcarriers AT wanglei fdgpetinpresymptomaticc9orf72mutationcarriers AT sossivesna fdgpetinpresymptomaticc9orf72mutationcarriers AT jacovaclaudia fdgpetinpresymptomaticc9orf72mutationcarriers AT bakermatt fdgpetinpresymptomaticc9orf72mutationcarriers AT shahinfardelham fdgpetinpresymptomaticc9orf72mutationcarriers AT rademakersrosa fdgpetinpresymptomaticc9orf72mutationcarriers AT mackenzieianra fdgpetinpresymptomaticc9orf72mutationcarriers AT hsiunggingyuekr fdgpetinpresymptomaticc9orf72mutationcarriers |